Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-10-25 (sudouest.fr)
France opposes a drug against Charcot's disease, patients protest
The High Health Authority has refused “early” access to this treatment, a procedure which allows reimbursement of a drug even though ongoing studies have not yet fully demonstrated its benefit.
Read more
2024-10-05 (pfarma.com.br)
Biogen launches "AME Cada Conquista" campaign with paralympic athlete Laissa Guerreira
This is the main action of the AME Cada Conquista campaign, an initiative to raise awareness about AME among young people and adults The biopharmaceutical Biog...
Read more
2024-09-26 (sanitainformazione.it)
World Ataxia Day: “Resign yourself! I dance with Friedreich"
At the center of the campaign is a docufilm: the protagonists are four patients and the actress Vittoria Belvedere, who as a mother of three teenagers wanted to give her contribution to shed light on the lives of young people who face this disease
Read more
2023-10-17 (e-fundresearch.com)
Amundi CPR Climate Action
Traditionally, the major US banks begin the reporting season that is now underway in the USA. At the
Read more
2023-07-31 (fiercepharma.com)
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
The ill-fated launch of Biogen’ s Alzheimer’ s disease treatment Aduhelm raised many questions, including this: Why did the FDA sign off on the drug after an independent advisory committee recommende| A study of FDA advisory committee meetings between 2010 and 2021 shows that the regulator leaned
Read more
2023-05-30 (endpts.com)
MarketingRx roundup: Biogen begins social awareness around postpartum depression; Pharma marketers in the NBA games
As Biogen and Sage Therapeutics await an FDA decision on postpartum depression (PPD) candidate zuranolone, they’re taking the first steps to drive awareness of the condition.
Read more
2023-05-30 (endpts.com)
Viatris re-ups medical education sponsorship pledge, adds health equity to primary care training
Viatris is adding to its sponsored medical education platform with new modules around health equity and social determinants of health. While an initiative called NCD Academy focuses on the five major contributing areas of non-communicable diseases( NCDs)— cardiovascular, diabetes, mental health,
Read more
2022-03-14 (fiercepharma.com)
UsAgainstAlzheimer's, spending millions to bat for Biogen's Aduhelm, launches TV and digital campaign
“ Alzheimer’ s patients can’ t wait”: That’ s the tagline of an unusual new campaign from UsAgainstAlzheimer’ s as the group looks to ramp up the pressure for Medicare to cover Biogen’ s controversial ne|“ Alzheimer’ s patients can’ t wait”: That’ s the tagline of an unusual new campaign from
Read more